Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 36 citing articles:

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
Siyu Lou, Zhiwei Cui, Yingyong Ou, et al.
BMC Psychiatry (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Safety of Janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022
Bahar Mikaeili, Zuhair Alqahtani, Ana L. Hincapie, et al.
Clinical Rheumatology (2025)
Open Access | Times Cited: 1
Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023
Yihan Yang, Sheng Wei, Huan Tian, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database
Wenwen Zhang, Yizhen Yin, Dan Yang, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database
Zhishen Ruan, Chunbin Wang, Shasha Yuan, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
Ke He, Kaidi Zhao, Tingyi Yin, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Real-world safety of maribavir: a retrospective study based on signal detection in the FDA adverse event reporting system
Qiang Gong, Linlin Zhang, Hui Wu, et al.
International Journal of Clinical Pharmacy (2025)
Closed Access
Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
Chuang Yang, Baoguo Deng, Qiang Wen, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
Shiyi Wang, Xiaojian Wang, Jing Ding, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
What does real-world data reveal about cangrelor’s safety? An analysis of FDA adverse event reporting system (FAERS) database
Zhaojun Wang, Junhang Zhang, Donglei Shi, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Safety evaluation of ILaris: a real-world analysis of adverse events based on the FAERS Database
Xun Yi, S. L. Wu, He He, et al.
Expert Opinion on Drug Safety (2025), pp. 1-13
Closed Access
A comprehensive exploration of adverse reactions to lapatinib: a disproportionate analysis based on the FAERS database
Yao Zhou, Jie Gong, Xianguang Deng, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
PREVENTABLE SERIOUS DRUG-DISEASE INTERACTIONS of RESERVE ANTIBIOTICS
Slobodan Јаnkovic, Snežana V. Janković, Dobrivoje Stojadinović
Expert Opinion on Drug Metabolism & Toxicology (2025)
Closed Access
Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants
Antonio Lombardi, Fran Pappas, Paul Bruinenberg, et al.
Antimicrobial Agents and Chemotherapy (2025)
Closed Access
Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system
Chengyu Zhu, Zhiwei Cui, Tingting Liu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS)
Zi Xue, Xi Liu, Qifeng Liu, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access
Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
Xiaoling Zhong, Yihan Yang, Sheng Wei, et al.
PLoS ONE (2025) Vol. 20, Iss. 3, pp. e0309849-e0309849
Open Access
Potential drugs associated with toxic epidermal necrolysis: a disproportionality analysis based on the FAERS database (2004–2024)
Xiaojian Li, Zhangren Yan, Shiyu Chen, et al.
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
A disproportionality analysis of hydrocortisone-related adverse events: a real-world pharmacovigilance study using the FAERS database
Xiaoyu Wang, Fan An, Xuelian Zhao, et al.
Expert Opinion on Drug Safety (2025), pp. 1-10
Closed Access
Study of adverse drug reactions during the treatment of drug resistant tuberculosis
Diya Dutta Gupta, Sanjivani Keny, Uday C. Kakodkar
Indian Journal of Tuberculosis (2024) Vol. 71, pp. S136-S140
Closed Access | Times Cited: 3
Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database
Yongli Hu, Yan Du, Zhisheng Qiu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Real-world research on beta-blocker usage trends in China and safety exploration based on the FDA Adverse Event Reporting System (FAERS)
Yilong Yan, Wentao An, Shenghui Mei, et al.
BMC Pharmacology and Toxicology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
Xiaoling Zhong, Yihan Yang, Sheng Wei, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups
Yingyong Ou, Zhiwei Cui, Siyu Lou, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
A real‑world pharmacovigilance study of raloxifene based on the FDA adverse event reporting system (FAERS)
Hao Liu, Wei Yan, Di Luo, et al.
Expert Opinion on Drug Safety (2024)
Closed Access
Page 1 - Next Page

Scroll to top